The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC's HZNP thyroid eye disorder drug and Epizyme Inc's EPZM tazemetostat for epithelioid sarcoma.

The Wuhan coronavirus scare triggered strong moves in stocks of companies working on treatment/vaccines for the deadly virus.

Here are the key catalysts that could impact trading in biotech stocks in the unfolding week.

Conferences

12th Annual T-cell Lymphoma Forum: Jan. 30–Feb. 1 in San Diego, California

PDUFA Dates

Aimmune Therapeutics Inc AIMT has a target action date of end of January for its peanut allergy treatment candidate Palforzia. An Adcom that evaluated the experimental therapy voted 7-to-2 in favor of the efficacy of Palforzia and 8-to-1 in favor of its safety.

See Also: 7 Blockbuster Drugs Expected To Be Launched In 2020

Clinical Readouts

Miragen Therapeutics Inc MGEN will make a poster presentation of data from the Phase 1 trial of cobomarsen, a miR inhibitor in patients with aggressive HTLV-1 Associated adult T-cell leukemia/lymphoma. The presentation is scheduled for Friday evening.

Earnings

Tuesday

• Pfizer Inc. PFE (before the market open)

Wednesday

• Illumina, Inc. ILMN (after the market close)
• Varian Medical Systems, Inc. VAR (after the market close)
• Hologic, Inc. HOLX

Thursday

• Quest Diagnostics Inc DGX (before the market open)
• Eli Lilly And Co LLY (before the market open)
• Biogen Inc BIIB (before the market open)
• Amgen, Inc. AMGN (after the market close)
• Edwards Lifesciences Corp EW (after the market close)

IPOs

Anpac Bio-Medical Science, which focuses on early cancer screening and detection, has filed to offer 17.50 million shares in an IPO, which is expected to be priced between $14 and $16. The company is seeking to list its shares on the Nasdaq under the ticker symbol "ANPC."

Arcutis Biotherapeutics, a biotech company developing topical therapies for common skin diseases, proposes to offer 7.8 million shares at a price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol "ARQT."

Black Diamond Therapeutics, a precision oncology company, is planning an 8.9-million share IPO to be priced between $16 and $18. The company expects to list the shares on the Nasdaq under the ticker symbol "BDTX."